Literature DB >> 24970783

30-year mortality after venous thromboembolism: a population-based cohort study.

Kirstine Kobberøe Søgaard1, Morten Schmidt2, Lars Pedersen2, Erzsébet Horváth-Puhó2, Henrik Toft Sørensen2.   

Abstract

BACKGROUND: Studies on long-term mortality after venous thromboembolism (VTE) are sparse. METHODS AND
RESULTS: Using Danish medical databases, we conducted a 30-year nationwide population-based cohort study of 128 223 patients with first-time VTE (1980-2011) and a comparison cohort of 640 760 people from the general population (without VTE) randomly matched by sex, year of birth, and calendar period. The mortality risks for patients with deep venous thrombosis (DVT) and pulmonary embolism (PE) were markedly higher than for the comparison cohort during the first year, especially within the first 30 days (3.0% and 31% versus 0.4%). Using Cox regression, we assessed mortality rate ratios (MRRs) with 95% confidence intervals (CIs). The overall 30-year MRR was 1.55 (95% CI, 1.53-1.57) for DVT and 2.77 (95% CI, 2.74-2.81) for PE. The 30-day MRR was 5.38 (95% CI, 5.00-5.80) for DVT and 80.87 (95% CI, 76.02-86.02) for PE. Over time, the 30-day MRR was consistently 5- to 6-fold increased for DVT, whereas it improved for PE from 138 (95% CI, 125-153) in 1980 to 1989 to 36.08 (95% CI, 32.65-39.87) in 2000 to 2011. The 1- to 10-year and 11- to 30-year MRRs remained 25% to 40% increased after both DVT and PE but were 3- to 5-fold increased after DVT and 6- to 11-fold increased after PE when VTE was considered the immediate cause of death.
CONCLUSIONS: Patients with VTE are at increased risk of dying, especially within the first year after diagnosis, but also during the entire 30 years of follow-up, with VTE as an important cause of death. Although 30-day mortality after DVT remained fairly constant over the last 3 decades, it improved markedly for PE.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  epidemiology; mortality; prognosis; thromboembolism

Mesh:

Year:  2014        PMID: 24970783     DOI: 10.1161/CIRCULATIONAHA.114.009107

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  64 in total

1.  Safety and effectiveness of direct oral anticoagulants following ultrasound-assisted catheter directed thrombolysis for venous thromboembolism.

Authors:  Denise Kelley; Laurence Wright; Kelsey Ohman; Jason Ferreira
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

2.  Venous thromboembolism. 30-year risk of death after VTE.

Authors:  Gregory B Lim
Journal:  Nat Rev Cardiol       Date:  2014-07-15       Impact factor: 32.419

3.  Arterial cardiovascular events and mortality following venous thromboembolism.

Authors:  Kasper Adelborg; Jens Sundbøll; Henrik Toft Sørensen
Journal:  Ann Transl Med       Date:  2015-06

4.  Claims-based or clinical models for predicting 90-day post-pulmonary embolism outcomes.

Authors:  Cecilia Becattini; Giancarlo Agnelli
Journal:  Intern Emerg Med       Date:  2017-05-22       Impact factor: 3.397

5.  Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study.

Authors:  Radhika Gangaraju; Yanjun Chen; Lindsey Hageman; Jessica Wu; Liton Francisco; Michelle Kung; Emily Ness; Mariel Parman; Daniel J Weisdorf; Stephen J Forman; Mukta Arora; Saro H Armenian; Smita Bhatia
Journal:  Br J Haematol       Date:  2019-03-18       Impact factor: 6.998

Review 6.  Real-world effectiveness and safety of pharmacological thromboprophylaxis in patients undergoing primary total hip and knee arthroplasty: A narrative review.

Authors:  Astrid Blicher Schelde; Astrid Eliasen; Jonas Bjerring Olesen; Thomas Bo Jensen; Espen Jimenez-Solem
Journal:  J Orthop       Date:  2019-11-12

7.  D-dimer measured at first venous thromboembolism is associated with future risk of cancer.

Authors:  Olga V Gran; Sigrid K Brækkan; Benedikte Paulsen; Hanne Skille; John-Bjarne Hansen
Journal:  Haematologica       Date:  2016-09-09       Impact factor: 9.941

8.  Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial.

Authors:  Igor A Suchkov; Javier Martinez-Gonzalez; Sebastian M Schellong; Toni Garbade; Michela Falciani
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 9.  Deep vein thrombosis: pathogenesis, diagnosis, and medical management.

Authors:  Jonathan Stone; Patrick Hangge; Hassan Albadawi; Alex Wallace; Fadi Shamoun; M Grace Knuttien; Sailendra Naidu; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

10.  Epidemiology of venous thromboembolism in the Framingham Heart Study.

Authors:  Marja K Puurunen; Philimon N Gona; Martin G Larson; Joanne M Murabito; Jared W Magnani; Christopher J O'Donnell
Journal:  Thromb Res       Date:  2016-06-29       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.